Novo Nordisk Slashes Ozempic Price by Half in US Market
Novo Nordisk Slashes Ozempic Price by Half in US Market Novo Nordisk has announced a significant reduction in the US price of its popular diabetes and weight-loss drug, Ozempic, effectively halving its cost for consumers. This move by the Danish pharmaceutical giant is expected to have a substantial impact on healthcare accessibility and affordability in the United States, particularly for the millions of Americans managing Type 2 diabetes and obesity. The decision comes amidst ongoing public and political pressure on…